(NASDAQ: AMLX) Amylyx Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.83%.
Amylyx Pharmaceuticals's revenue in 2025 is -$1,272,000.On average, 1 Wall Street analysts forecast AMLX's revenue for 2026 to be $57,941,707, with the lowest AMLX revenue forecast at $57,941,707, and the highest AMLX revenue forecast at $57,941,707. On average, 2 Wall Street analysts forecast AMLX's revenue for 2027 to be $2,458,511,179, with the lowest AMLX revenue forecast at $1,128,526,161, and the highest AMLX revenue forecast at $3,788,496,198.
In 2028, AMLX is forecast to generate $8,269,172,936 in revenue, with the lowest revenue forecast at $3,942,710,278 and the highest revenue forecast at $12,595,635,593.